(Q28246535)

2

Frederik Barkhof

0 references

David H. Miller

1

David Miller

0 references

Alan J. Thompson

4

Alan Thompson

0 references

Xavier Montalban

3

Relapses and progression of disability in multiple sclerosis

Xavier Montalban

0 references

language of work or name

English

0 references

publication date

May 2005

0 references

published in

Lancet Neurology

0 references

volume

4

0 references

issue

5

0 references

page(s)

281-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The natural history of multiple sclerosis: a regional study with some longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Is optic neuritis more benign than other first attacks in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Cognitive impairment in patients with clinically isolated lesions of the type seen in multiple sclerosis. A psychometric and MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Cortical lesions in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

A long-term prospective study of optic neuritis: evaluation of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

CD4 T cell activation and disease activity at onset of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Optic neuritis: chemokine receptor CXCR3 and its ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Development of biomarkers in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Management of acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Magnetic resonance imaging in clinically isolated lesions of the brain stem

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Magnetic resonance imaging in isolated noncompressive spinal cord syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Assessment of MRI criteria for a diagnosis of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

New diagnostic criteria for multiple sclerosis: application in first demyelinating episode

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Long‐term follow‐up of acute partial transverse myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Spinal cord MRI in clinically isolated optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The early risk of multiple sclerosis after optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

Neurologic impairment 10 years after optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970071-5

7 January 2021

10.1016/S1474-4422(05)70071-5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15847841

1 reference

Consolidated OpenCitations Corpus – April 2017